First-in-human study of IPH4102 for relapsed cutaneous T-cell lymphoma

First-in-human study of IPH4102 for relapsed cutaneous T-cell lymphoma

VJHemOnc

1 year
183 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Martine Bagot, MD, PhD, of Saint Louis Hospital, Paris, France, speaks at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, on the progress of a new monoclonal antibody, IPH4102, being trialed for the first time in humans (NCT02593045). Prof. Bagot describes the results of the KIR3DL2-targeting antibody currently in Phase I of development, highlighting the plan to conduct the drug's Phase II clinical trial in 2019 on patients of Sézary syndrome, mycosis fungoides and nodal peripheral T-cell lymphoma.
Up Next Autoplay
Accelerating clinical trials in transplantation
Accelerating clinical trials in transplantation
Category: Acute Myelogenous Leukemia
1,218 Views
VJHemOnc 1 year
Whole genome sequencing opens door for targeted Waldenström’s therapy
Whole genome sequencing opens door for targeted Waldenström’s therapy
Category: Multiple Myeloma
821 Views
VJHemOnc 1 year
Updated POLLUX results for early relapsed myeloma patients
Updated POLLUX results for early relapsed myeloma patients
Category: Multiple Myeloma
935 Views
VJHemOnc 1 year
Targeting BCMA with bispecific antibodies in R/R myeloma
Targeting BCMA with bispecific antibodies in R/R myeloma
Category: Multiple Myeloma
969 Views
VJHemOnc 1 year
Monoclonal antibodies: current and future potential
Monoclonal antibodies: current and future potential
Category: General
767 Views
VJHemOnc 1 year
Plasma cell leukemia and extramedullary disease in multiple myeloma
Plasma cell leukemia and extramedullary disease in multiple myeloma
Category: General
275 Views
VJHemOnc 1 year
Judging the value of a clinical trial in hem-onc
Judging the value of a clinical trial in hem-onc
Category: General
54 Views
VJHemOnc 1 year
Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma
Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma
Category: Multiple Myeloma
100 Views
VJHemOnc 1 year
Future treatment combinations for myeloma
Future treatment combinations for myeloma
Category: Melanoma and Skin Cancer
124 Views
VJHemOnc 1 year
Continuous vs. fixed duration therapy for multiple myeloma?
Continuous vs. fixed duration therapy for multiple myeloma?
Category: Multiple Myeloma
60 Views
VJHemOnc 1 year